查詢結果分析
相關文獻
- Late Recurrences in Luminal-like Breast Cancer
- In-Depth Evaluation of the AJCC 2010 Staging System for Luminal-Like Breast Cancer--An Analysis from a Free-Standing Cancer Hospital
- 晚期雌激素受體陽性乳癌患者治療進展之綜論
- Secondary Surgical Correction via Virtual Simulation Planning in Delayed Relapse Facial Asymmetrya--A Case Report
頁籤選單縮合
題 名 | Late Recurrences in Luminal-like Breast Cancer=管腔樣乳癌延遲復發分析 |
---|---|
作 者 | 鄭鴻鈞; 余本隆; 洪振芳; 陳啟明; 褚乃銘; 曹美華; 林寬仁; 劉美瑾; 黃達夫; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 28:4 2012.12[民101.12] |
頁 次 | 頁149-160 |
分類號 | 416.226 |
關鍵詞 | 管腔樣乳癌; 延遲復發; 激素受體陽性; HER2陰性; Luminal-like breast cancer; Late recurrence; Hormonal receptor positive; HER2-negative; |
語 文 | 英文(English) |
中文摘要 | 目的:這項研究目的在(1)瞭解管腔樣乳癌(Luminal like breast cancer,激素受體陽性和 HER2 陰性)的疾病特性和延遲復發的情形,及(2)找出與疾病復發相關的預後因素。 材料和方法:1990 年和 2007 年之間,在我們機構最初的治療為手術的乳癌病人,被納入 本研究。這些病人也應符合以下條件:(1)病理分期的 I-III,(2)激素受體陽性,(3) HER2/neu 無過度表達(陰性)。合計有 1763 例病人均符合要求。1275(72%),937(53%) 和 1629(92%)的病人,分別給予輔助化療,放療和激素治療。 Cox 比例風險回歸模型 被用來評估有關疾病復發的危險因素預後的意義。 結果:第一期的病人,五年和十年的無病生存率分別為 96%和 91%,第二期的病人為 90% 和 81%,第三期病人為 79%和 65%。在第ㄧ個 5 年復發的年發病率幾乎等於第二個 5 年 的年發病率。多變量分析表明,獨立危險因素為年齡≤40(風險 1.8 倍,95%的信心區間 [CI],1.4~2.5),腫瘤> 2 厘米(風險 1.6 倍,95%CI,1.1-2.1),腋窩淋巴結陽性(陽 性數目 1-3/4-9 /≥10 ,風險分別為 1.9/2.0/3.9 倍,95%CI,1.3-2.8/1.2-3.4/2.2-6.8),核 III 級(風險 1.4 倍,95%CI,1.1 - 1.9), 淋巴結包膜侵犯(風險 1.6 倍,95%CI,1.1-2.30), 輔助激素治療(風險 0.48 倍,95%CI,0.30-0.76)。 結論:管腔類乳癌(激素受體陽性和 HER2 陰性)有良好的長期生存結果,但有不少的 後期復發。對於≤ 40 歲的病人,腫瘤> 2 厘米,腋窩淋巴結轉移,核 III 級,淋巴結包膜 侵犯,其復發的風險也相對較高。對於這些高風險的乳癌病人,尤其是年齡在 40 歲或以 下的病人,設計針對性的臨床試驗。 |
英文摘要 | Purpose: The intention of this study is to both examine the disease entity and late recurrences of luminal-like (hormonal receptor positive and HER2-negative) breast cancer, and identify the prognostic factors associated with disease recurrences. Materials and Methods: We selected for this study breast cancer patients initially treated with primary surgeries in our institution between 1990 and 2007, who also fit the following criteria: 1) pathology stage I-III, 2) hormonal receptor-positive, and 3) HER2/neu-negative. Out of the total 1763 eligible patients, 1275 (72%) received adjuvant chemotherapy, 937 (53%) underwent radiotherapy, and 1629 (92%) had hormonal therapy. Cox proportional hazards regression models were used to assess the prognostic significance of the risk factors related to disease recurrences. Results: The five- and ten-year disease-free survival rates were 96% and 91% for stage I patients, 90% and 81% for stage II, and 79% and 65% for stage III patients, respectively. The incidence of recurrence at each stage in the first 5 years was almost equal to that in the second 5 years. The independent risk factors, according to the multivariate analysis, were: age ≤ 40 (hazard ratio [HR] 1.8, 95% confidence interval [CI], 1.4-2.5); tumor > 2cm (HR 1.6, 95% CI, 1.1-2.1); axillary lymph node positive (HR 1.9/2.0/3.9, 95% CI, 1.3-2.8/1.2-3.4/2.2-6.8 for node positive 1-3/4-9/≥10, respectively); nuclear grade III (HR 1.4, 95% CI, 1.1-1.9); the presence of ECS (HR 1.6, 95% CI, 1.1-2.30); and adjuvant hormonal therapy (HR 0.48, 95% CI, 0.30-0.76). Conclusions: Luminal-like (hormonal receptor positive and HER2-negative) breast cancer has excellent long-term outcomes, but also has a considerable frequency of late recurrences. The risk of breast cancer recurrence is relatively high for patients ≤ 40 years of age, with tumor size greater than 2cm, with axillary LN metastasis, status of nuclear grade III, or with ECS involvement. Clinical trials should be considered for these high-risk breast cancer patients, especially for patients who are diagnosed at 40 years of age or younger. |
本系統中英文摘要資訊取自各篇刊載內容。